Remington-Davis, Inc | Columbus, OH

Research site

(Unclaimed)

Location

1335 Dublin Road, Suite 106A, Columbus, Ohio, United States of America

Site insights

Top conditions

Top treatments

Orforglipron

LY3502970

Ritlecitinib

RTA 901

Tanezumab

LY3471851

Difamilast

Peramivir

Bimagrumab

Zidovudine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 46 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Active, not recruiting

Cough

Refractory Chronic Cough

Drug: BLU-5937

Drug: Placebo

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (Tranquillo LTE)

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Active, not recruiting

Vitiligo

Drug: Ritlecitinib

Drug: Ritlecitinib 100 mg

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Active, not recruiting

Hypertension

Drug: Orforglipron

Drug: Placebo

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Active, not recruiting

Hypertension

Overweight or Obesity

Drug: Placebo

Drug: Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Active, not recruiting

Hypertension

Drug: Orforglipron

Drug: Placebo

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. R...

Enrolling

Healthy

Biological: V350A

Biological: Placebo

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in t...

Enrolling

COVID-19 SARS-CoV-2 Infection

Drug: placebo

Drug: ibuzatrelvir

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Active, not recruiting

Arteriosclerosis

Hypercholesterolaemia

Drug: Enlicitide Decanoate

Drug: Placebo

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough (ASPIRE)

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling

Refractory or Unexplained Chronic Cough

Drug: NOC-110

Other: Placebo

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD (Cardinal COPD)

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduc...

Enrolling

Rhinovirus Infection

Other: Placebo

Drug: VPV 500 mg